Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7ZCE

SARS-CoV-2 Spike protein in complex with the single chain fragment scFv76

Summary for 7ZCE
Entry DOI10.2210/pdb7zce/pdb
EMDB information14628
DescriptorSpike glycoprotein,Fibritin, scFv76 single chain fragment, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (4 entities in total)
Functional Keywordssars-cov-2, spike, single chain fragment, viral protein
Biological sourceSevere acute respiratory syndrome coronavirus 2
More
Total number of polymer chains6
Total formula weight522470.58
Authors
Chaves-Sanjuan, A.,Bolognesi, M. (deposition date: 2022-03-28, release date: 2022-10-12, Last modification date: 2024-11-20)
Primary citationMilazzo, F.M.,Chaves-Sanjuan, A.,Minenkova, O.,Santapaola, D.,Anastasi, A.M.,Battistuzzi, G.,Chiapparino, C.,Rosi, A.,Merlo Pich, E.,Albertoni, C.,Marra, E.,Luberto, L.,Viollet, C.,Spagnoli, L.G.,Riccio, A.,Rossi, A.,Santoro, M.G.,Ballabio, F.,Paissoni, C.,Camilloni, C.,Bolognesi, M.,De Santis, R.
Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol delivery.
Mol.Ther., 31:362-373, 2022
Cited by
PubMed Abstract: The uneven worldwide vaccination coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and emergence of variants escaping immunity call for broadly effective and easily deployable therapeutic agents. We have previously described the human single-chain scFv76 antibody, which recognizes SARS-CoV-2 Alpha, Beta, Gamma and Delta variants. We now show that scFv76 also neutralizes the infectivity and fusogenic activity of the Omicron BA.1 and BA.2 variants. Cryoelectron microscopy (cryo-EM) analysis reveals that scFv76 binds to a well-conserved SARS-CoV-2 spike epitope, providing the structural basis for its broad-spectrum activity. We demonstrate that nebulized scFv76 has therapeutic efficacy in a severe hACE2 transgenic mouse model of coronavirus disease 2019 (COVID-19) pneumonia, as shown by body weight and pulmonary viral load data. Counteraction of infection correlates with inhibition of lung inflammation, as observed by histopathology and expression of inflammatory cytokines and chemokines. Biomarkers of pulmonary endothelial damage were also significantly reduced in scFv76-treated mice. The results support use of nebulized scFv76 for COVID-19 induced by any SARS-CoV-2 variants that have emerged so far.
PubMed: 36114671
DOI: 10.1016/j.ymthe.2022.09.010
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (3.5 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon